Semax
Clinically used in Russia; recent peer-reviewed work is largely preclinical (stroke, cognition, neuroprotection).
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in an Animal Model of Alzheimerβs Disease
In transgenic APP/PS1 mice, the authors observed that Semax and a derivative peptide were associated with improved performance on behavioural cognition tests and a reduced number of amyloid inclusions in the cortex and hippocampus.
View study βACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke
In a rat experimental-stroke model, the authors reported that Semax shifted the ischemia-disrupted brain gene-expression profile, decreasing inflammatory-cluster gene expression and increasing neurotransmitter-cluster gene expression at 24 hours.
View study βNeuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries
This review of peptide-based neuroprotective strategies for ischemic stroke summarised RNA-sequencing evidence that Semax suppresses inflammatory gene expression and activates neurotransmission-related genes following ischemic injury in rodent models.
View study βSemax, a Synthetic Regulatory Peptide, Affects Copper-Induced AΞ² Aggregation and Amyloid Formation in Artificial Membrane Models
In biophysical and cell-based experiments, the authors reported that Semax interfered with copper-mediated amyloid-Ξ² aggregation, reduced oligomer and fibre formation, and protected neuroblastoma cells from amyloid-Ξ²-induced toxicity.
View study βProvided for educational and reference purposes only. These materials are sold strictly for laboratory research and are not for human or animal use.